Neurescue develops cardiovascular solutions centered on the NEURESCUE system, a computer-aided balloon catheter for aortic occlusion designed to increase blood flow to the brain and heart during cardiac arrest. The NEURESCUE device comprises a catheter and control unit that use patented sensor guidance, automated inflation technology, and a safety feedback system to ensure precise positioning and regulate balloon pressure. In emergency situations the device can boost blood flow within one minute, aiming to raise resuscitation rates and provide additional time for advanced interventions. The company received FDA approval for the NEURESCUE device two and a half years ago. Neurescue was founded by Dr. Habib Frost and is described in the article as a nine-year-old, Copenhagen-based company. It has just completed a Series A round, securing DKK 50M (approximately €6.7M) to further develop and deploy its cardiovascular devices.

Total raised

$7M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2024